SRNE Sorrento Therapeutics, Inc. Stock Quote

SRNE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.55	Insider Own	5.79%	Shs Outstand	337.12M	Perf Week	-7.64%
Market Cap	560.40M	Forward P/E	0.17	EPS next Y	8.42	Insider Trans	-0.01%	Shs Float	312.41M	Perf Month	-17.61%
Income	-471.70M	PEG	-	EPS next Q	-0.25	Inst Own	33.60%	Short Float	17.49%	Perf Quarter	-43.36%
Sales	57.00M	P/S	9.83	EPS this Y	-11.90%	Inst Trans	37.94%	Short Ratio	5.70	Perf Half Y	-76.54%
Book/sh	0.67	P/B	2.16	EPS next Y	995.70%	ROA	-	Target Price	21.00	Perf Year	-79.46%
Cash/sh	0.70	P/C	2.07	EPS next 5Y	37.00%	ROE	-	52W Range	1.15 - 11.07	Perf YTD	-68.82%
Dividend	-	P/FCF	-	EPS past 5Y	-3.70%	ROI	-169.30%	52W High	-86.90%	Beta	2.36
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	45.40%	Gross Margin	73.00%	52W Low	26.09%	ATR	0.14
Employees	799	Current Ratio	1.60	Sales Q/Q	28.70%	Oper. Margin	-	RSI (14)	40.97	Volatility	7.93% 9.49%
Optionable	Yes	Debt/Eq	0.68	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.60	Prev Close	1.58
Shortable	Yes	LT Debt/Eq	0.42	Earnings	-	Payout	-	Avg Volume	9.59M	Price	1.45
Recom	2.00	SMA20	-4.86%	SMA50	-24.22%	SMA200	-70.20%	Volume	5,727,081	Change	-8.23%

Jan-29-21

Initiated

B. Riley Securities

Buy

$26

Jan-21-21

Initiated

Alliance Global Partners

Buy

$35

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$24 → $30

May-26-20

Initiated

Dawson James

Buy

$24

Oct-07-19

Initiated

JMP Securities

Mkt Outperform

$21

Jun-28-18

Initiated

B. Riley FBR, Inc.

Buy

$14.25

Jan-16-18

Reiterated

H.C. Wainwright

Buy

$20 → $30

May-22-17

Reiterated

Rodman & Renshaw

Buy

$30 → $20

May-22-17

Reiterated

FBR & Co.

Outperform

$13 → $9

Oct-03-16

Initiated

ROTH Capital

Buy

Apr-06-16

Reiterated

FBR Capital

Outperform

$21 → $16

Mar-16-16

Reiterated

FBR Capital

Outperform

$22 → $21

Dec-22-15

Initiated

FBR Capital

Outperform

$22

Dec-07-15

Resumed

Rodman & Renshaw

Buy

$45

Aug-03-15

Resumed

MLV & Co

Buy

$34

Jul-29-15

Reiterated

Brean Capital

Buy

$17 → $26

May-28-15

Initiated

Brean Capital

Buy

$17

Mar-17-15

Reiterated

H.C. Wainwright

Buy

$13 → $20

Oct-02-14

Initiated

H.C. Wainwright

Buy

$11

Jun-19-14

Initiated

MLV & Co

Buy

May-18-22 09:30AM	Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain GlobeNewswire
09:00AM	Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors GlobeNewswire
May-17-22 03:52PM	Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer Benzinga +9.03%
11:00AM	Sorrentos License Partner, Lees Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) GlobeNewswire
09:00AM	Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial) GlobeNewswire
08:25AM	Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates Zacks
May-16-22 05:15PM	Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates Zacks
09:00AM	Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination between Scilex and Vickers GlobeNewswire
May-12-22 08:25AM	Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-11-22 09:00AM	Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia GlobeNewswire -12.68%
May-05-22 08:05PM	Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting GlobeNewswire -7.51%
May-03-22 09:15AM	Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients GlobeNewswire
May-02-22 06:54PM	Why Sorrento Therapeutics Stock Shot 7% Higher Today Motley Fool +7.28%
09:00AM	Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern GlobeNewswire
Apr-28-22 09:00AM	Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO) GlobeNewswire
Apr-27-22 09:00AM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV. GlobeNewswire
Apr-25-22 12:46PM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies GlobeNewswire
09:30AM	Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern GlobeNewswire
09:00AM	Dr. Henry Ji, Sorrento Therapeutics Chairman and CEO and Scilex Holding Companys Executive Chairman, to Present at the B. Riley Securities 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022) GlobeNewswire
Apr-19-22 03:43PM	Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today Motley Fool
Apr-12-22 09:15PM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill GlobeNewswire
Apr-04-22 09:00AM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022 GlobeNewswire
Mar-31-22 05:55PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates Zacks
09:00AM	Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19 GlobeNewswire
Mar-29-22 05:55PM	CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates Zacks
09:00AM	Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel GlobeNewswire
Mar-27-22 08:00AM	Which Company Has the Biggest COVID Program? The Answer Isn't Moderna. Motley Fool
Mar-25-22 09:00AM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I GlobeNewswire
Mar-24-22 08:55AM	InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
Mar-20-22 05:26PM	Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants GlobeNewswire
Mar-18-22 05:30PM	Why Sorrento Therapeutics Stock Bumped Higher Today Motley Fool
12:02PM	Sorrento's Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management Benzinga
09:00AM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity GlobeNewswire
Mar-17-22 03:35PM	Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I GlobeNewswire +7.92%
Mar-15-22 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates Zacks +8.00%
Mar-10-22 09:45AM	AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates Zacks
Mar-02-22 11:37AM	Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure GlobeNewswire
11:24AM	Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses GlobeNewswire
Feb-24-22 06:20PM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-22-22 09:00AM	Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses GlobeNewswire
Feb-17-22 01:02PM	Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX GlobeNewswire -5.57%
Feb-11-22 03:00PM	Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-07-22 10:45AM	2 Beaten-Down Biotech Stocks That Could Make You Filthy Rich Motley Fool
Feb-02-22 03:38PM	Sorrento Therapeutics CEO details Covishield neutralizing antibody Yahoo Finance Video -7.51%
Feb-01-22 09:00AM	Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis GlobeNewswire
Jan-28-22 09:00AM	Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron GlobeNewswire
08:30AM	Why Sorrento Therapeutics Stock Is Getting Hammered This Week Motley Fool
Jan-26-22 05:38PM	TL Private Wealth Buys FIRST TR EXCHANGE, Apple Inc, Sells Invesco Emerging Markets Sovereign ... GuruFocus.com -7.12%
Jan-24-22 09:00AM	Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary Sorrento Mexico for February Delivery in Mexico GlobeNewswire -7.10%
Jan-21-22 07:00AM	Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2 GlobeNewswire -8.75%
Jan-20-22 05:38PM	Donald L. Hagan, LLC Buys Day Hagan/Ned Davis Research Smart Sector Fixed In, SPDR Portfolio ... GuruFocus.com
09:25AM	Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant Benzinga
09:00AM	SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2 PR Newswire
Jan-19-22 02:26PM	Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico GlobeNewswire
10:35AM	Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK GlobeNewswire
Jan-18-22 09:00AM	Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler) GlobeNewswire -7.24%
Jan-13-22 10:14AM	Sorrento Therapeutics Mexico Wins Tender to Sell COVISTIX Tests to Mexico City Government GlobeNewswire
Jan-10-22 01:35PM	Does Sorrento Therapeutics (NASDAQ:SRNE) Have A Healthy Balance Sheet? Simply Wall St.
Jan-07-22 05:00PM	Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer GlobeNewswire
11:20AM	Dr. Henry Ji to Present at HC Wainwright BIOCONNECT Virtual Conference (January 10th 13th) GlobeNewswire
Jan-06-22 05:38PM	Versant Capital Management, Inc Buys Dimensional World ex U.S. ... GuruFocus.com
Jan-04-22 09:00AM	Dr. Henry Ji to Participate in Longwood Healthcare Leaders Winter Webconference Panel on January 6th 2022 GlobeNewswire
Dec-31-21 05:56AM	Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week Motley Fool -5.10%
Dec-29-21 11:17AM	NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today? InvestorPlace
Dec-28-21 04:48PM	Sorrento: Theres Huge Upside in Store for This Overlooked Stock, Says Analyst TipRanks -11.85%
Dec-27-21 09:42AM	Sorrento Therapeutics' Covistix rapid tests outperforms in detecting omicron variant in initial lab tests MarketWatch
09:23AM	Sorrento Therapeutics triples number of its rapid COVID-19 tests distributed in Mexico MarketWatch
09:20AM	Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant GlobeNewswire
09:00AM	Sorrento Therapeutics Mexico Executes Second Contract for Sale of 10 Million COVISTIX Tests for Mexico Market GlobeNewswire
Dec-21-21 04:22AM	DYAI: Jumpin Janssen Jamboree Zacks Small Cap Research
Dec-20-21 09:00AM	Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors GlobeNewswire
Dec-13-21 11:33AM	Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options Zacks
Dec-09-21 09:00AM	Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy GlobeNewswire
Dec-07-21 01:42PM	Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA) GlobeNewswire +13.33%
09:00AM	Sorrento Therapeutics Clinical Laboratory Receives Accreditation From the College of American Pathologists GlobeNewswire
Dec-06-21 02:41PM	Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil GlobeNewswire +6.17%
09:00AM	Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (SPAC) Enter into Letter of Intent for Proposed Business Combination GlobeNewswire
Dec-05-21 02:28PM	Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron GlobeNewswire
Nov-30-21 09:00AM	Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference GlobeNewswire
Nov-29-21 09:00AM	Sorrento Publishes an Abivertinib Teaser Entitled Abivertinib A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases GlobeNewswire
Nov-22-21 02:53PM	Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market GlobeNewswire
Nov-16-21 05:17PM	With Progress on Multiple Fronts, Sorrento Stock Is a Great Buy: Analyst TipRanks
Nov-12-21 03:19PM	Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City GlobeNewswire
09:00AM	Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research GlobeNewswire
Nov-11-21 08:00AM	DYAI: Two New Deals & A Pharma in the Wings Zacks Small Cap Research
Nov-07-21 01:08PM	Sorrento Awarded California Competes Tax Credit GlobeNewswire
Nov-03-21 10:06AM	Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX (COVID-19 Virus Antigen Detection Test) for Brazil GlobeNewswire
Nov-01-21 09:00AM	Sorrentos License Partner, Lees Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer GlobeNewswire
Oct-29-21 03:00PM	Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-27-21 03:58PM	UPDATE Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients GlobeNewswire
02:26PM	Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients GlobeNewswire
Oct-26-21 06:11PM	Sorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst TipRanks
Oct-20-21 01:37PM	Sorrento Announces That COVISTIX (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device GlobeNewswire
Oct-13-21 09:30AM	Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors GlobeNewswire
09:00AM	FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain GlobeNewswire
Oct-04-21 12:50AM	Hedge Funds Are Dumping Sorrento Therapeutics Inc (SRNE) Insider Monkey -6.89%
Sep-28-21 02:23PM	CORRECTION - Sorrento Therapeutics, Inc. GlobeNewswire -7.00%
12:23PM	Sorrento to Participate in the Benzinga Healthcare Small Cap Conference on September 30th GlobeNewswire
Sep-27-21 01:13PM	Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021 GlobeNewswire
Sep-19-21 02:58PM	Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test GlobeNewswire

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Janda Kim	Director	Dec 27	Option Exercise	4.00	3,000	12,000	6,000	Dec 27 07:34 PM
Janda Kim	Director	Dec 27	Sale	5.88	3,000	17,640	3,000	Dec 27 07:34 PM
Ji Henry	See Remarks	Sep 29	Option Exercise	4.00	10,000	40,000	2,055,807	Sep 29 02:35 PM
Janda Kim	Director	Sep 27	Option Exercise	2.11	42,357	89,264	45,357	Sep 28 05:37 PM
Janda Kim	Director	Sep 27	Sale	8.02	42,357	339,720	3,000	Sep 28 05:37 PM
Janda Kim	Director	Sep 13	Option Exercise	3.50	8,000	28,000	11,000	Sep 14 05:00 PM
Janda Kim	Director	Sep 13	Sale	8.04	8,000	64,285	3,000	Sep 14 05:00 PM
Smith Robin L	Director	Sep 03	Option Exercise	4.49	175,000	785,250	235,000	Sep 03 05:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience